



MAIL STOP - AMENDMENT  
Docket No.: 26589U

*DFW mark*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor: KAUTZ, et al.

Group Art Unit: 1614

Serial Number: 10/524,820 ✓

Examiner: UNKNOWN

Filing Date: February 18, 2005

Confirmation No.: 1645

Title: 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS


**THE PTO STAMP HEREON ACKNOWLEDGES RECEIPT OF:**

1. Supplemental Information Disclosure Statement;
2. Supplemental PTO Form-1449 with 20 references cited; and
3. Copies of 18 of the 20 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,  
**THE NATH LAW GROUP PLLC**

February 9, 2007

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

ct



MAIL STOP - AMENDMENT

Docket No.: 26589U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: KAUTZ, et al.

Group Art Unit: 1614

Serial Number: 10/524,820

Examiner: UNKNOWN

Filing Date: February 18, 2005

Confirmation No.: 1645

Title: 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

A Supplemental Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. ☒ The enclosed supplemental statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. ☐ The enclosed supplemental statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed supplemental statement is accompanied by [check one]:

☐ i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

☐ ii. a check in the amount required by 37 C.F.R. 1.17(p).

c. ☐ The enclosed supplemental statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311,

**MAIL STOP - AMENDMENT**

Docket No.: 26589U

but before payment of the issue fee.

☐ Certification report(e) below; and .

☐ a check in the amount as required by 1.17(p).

d. ☐ The enclosed supplemental statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Supplemental Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

or

☐ Appropriate certification is attached.

f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XXX] Copies of the documents are attached herewith with a completed Supplemental PTO Form-1449.

or

[ ] Copies of the documents are not attached, with a completed Supplemental PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or


[XXX] Copies of US Patents/Publications not attached, with a completed Supplemental PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Supplemental PTO Form-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Supplemental PTO Form-1449, and return a copy of the initialed Supplemental PTO Form-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.


If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**THE NATH LAW GROUP PLLC**

February 8, 2007

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375.

ct



MAIL STOP - AMENDMENT

Docket No.: 26589U

**SUPPLEMENTAL**  
**PTO FORM-1449**

**INFORMATION DISCLOSURE**  
**CITATION**

Inventor: KAUTZ

Appl. No.:  
10/524,820

Art Unit: 1614

Examiner: UNKNOWN

Appl. Filing Date:  
February 18, 2005

Confirm. No.: 1645

**U.S. PATENT DOCUMENTS**

Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
	A1	6,476,025	05 Nov 2002	Gutterer	12 Jan 2000
	A2	6,306,869	23 Oct 2001	Flockerzi	27 Apr 1999
	A3				
	A4				

**FOREIGN PATENT DOCUMENTS**

Exam. Initial		Document No.	Public. Date	Country	Translation
	A5	00/42034 A1	20 Jul 2000	WO	n/a
	A6	2005/090311 A1	29 Sep 2005	WO	n/a
	A7	2005/077906 A1	25 Aug 2005	WO	n/a
	A8	2005/085225 A1	15 Sep 2005	WO	n/a
	A9	2005/084104 A2	15 Sep 2005	WO	n/a
	A10	2005/085203 A1	15 Sep 2005	WO	n/a
	A11	2005/087745 A1	22 Sep 2005	WO	n/a
	A12	2005/087744 A1	22 Sep 2005	WO	n/a
	A13	2006/092422 A1	08 Sep 2006	WO	n/a
	A14	02/066476 A1	29 Aug 2002	WO	n/a
	A15	2004/018431 A2	04 Mar 2004	WO	n/a
	A16	00/42019 A1	20 Jul 2000	WO	n/a
	A17	02/06270 A1	24 Jan 2002	WO	n/a
	A18	00/42017 A1	20 Jul 2000	WO	n/a
	A19				
	A20				

**OTHER**

Exam. Initial		(Including Author, Title, Date, Pertinent Pages, etc.)
	A21	"Souness, J.E., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors". <u>Immunopharmacology</u> , Vol. 47, pg. 127-162, 2000".
	A22	"Dyke, H.J., "Update on the therapeutic potential of PDE4 inhibitors". <u>Expert Opinion on Investigational Drugs</u> , Vol. 11, No. 1, pg. 1-13, 2002".
	A23	"Montana, J., "Chapter 5. Phosphodiesterase 4 Inhibitors". <u>Annual Reports Med Chem</u> , Vol. 36, pg. 47-56, 2001.
	A24	"Schmidt, B.J., "The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis". <u>Allergy Clin Immunol</u> , Vol. 108, pg. 530-536, 2001".
	A25	
	A26	

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.